Clinical Trials · NCT02380521
Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- University of Palermo
- Enrollment
- 60
- Start date
- Jan 2015
- Locations
- 1 site, Italy
- Primary endpoint
- Subclinical atherosclerosis (as measured by cIMT) in patients with T2DM treated with exenatide once weekly